CoChat

Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats

Yoshiji, Hitoshi, Noguchi, Ryuichi, Kuriyama, Shigeki, Ikenaka, Yasuhide, Yoshii, Junichi, Yanase, Koji, Namisaki, Tadashi, Kitade, Mitsuteru, Masaki, Tsutomu, Fukui, Hiroshi · 2005 · American Journal of Physiology-Gastrointestinal and Liver Physiology
Cited by 145

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

It is widely recognized that activated hepatic stellate cells (HSC) play a pivotal role in development of liver fibrosis. A platelet-derived growth factor (PDGF) is the most potent mitogen for HSC. The aim of this study was to examine the effect of imatinib mesylate (STI-571, Gleevec), a clinically used PDGF receptor (PDGFR) tyrosine kinase inhibitor, on development of experimental liver fibrosis. The rat model of pig serum-induced hepatic fibrosis was used to assess the effect of daily oral administration of STI-571 on the indexes of fibrosis. STI-571 markedly attenuated development of liver fibrosis and hepatic hydroxyproline and serum fibrosis markers. The number of α-smooth muscle actin-positive cells and mRNA expression of α 2-(I)-procollagen, tissue inhibitor of metalloproteinases-1, and transforming growth factor-β were also significantly suppressed by STI-571. Our in vitro study showed that STI-571 markedly attenuated PDGF-BB-induced proliferation and migration and α-SMA and α 2-(I)-procollagen mRNA of activated HSC in a dose-dependent manner. STI-571 also significantly attenuated PDGF-BB-induced phosphorylation of PDGFR-β, MEK1/2, and Akt in activated HSC. Because STI-571 is widely used in clinical practice, it may provide an effective new strategy for antifibrosis therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1152/ajpgi.00420.2004

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 145

Metadata

Authors
Yoshiji, H., Noguchi, R., Kuriyama, S., Ikenaka, Y., Yoshii, J., Yanase, K., Namisaki, T., Kitade, M., Masaki, T., & Fukui, H.
Venue
American Journal of Physiology-Gastrointestinal and Liver Physiology
Published
2005-05
Volume
288
Issue
5
Pages
G907-G913
ISSN
  • 0193-1857 (ISSN-L)
  • 1522-1547
OpenAlex
W2108518428
Cited by
145
References
3
FWCI
5.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. https://app.cochat.ai/papers/10.1152/ajpgi.00420.2004
The paper
Yoshiji, H., Noguchi, R., Kuriyama, S., Ikenaka, Y., Yoshii, J., Yanase, K., Namisaki, T., Kitade, M., Masaki, T., & Fukui, H. (2005). Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00420.2004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.